These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12570681)

  • 1. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme.
    Cohen KA; Liu T; Bissonette R; Puri RK; Frankel AE
    Curr Pharm Biotechnol; 2003 Feb; 4(1):39-49. PubMed ID: 12570681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.
    Liu TF; Hall PD; Cohen KA; Willingham MC; Cai J; Thorburn A; Frankel AE
    Clin Cancer Res; 2005 Jan; 11(1):329-34. PubMed ID: 15671563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture.
    Liu TF; Cohen KA; Willingham MC; Tatter SB; Puri RK; Frankel AE
    J Neurooncol; 2003 Oct; 65(1):77-85. PubMed ID: 14649887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells.
    Mishra G; Liu TF; Frankel AE
    Expert Opin Biol Ther; 2003 Oct; 3(7):1173-80. PubMed ID: 14519080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF).
    Osborne CK; Coronado-Heinsohn E
    Cancer J Sci Am; 1996; 2(3):175-80. PubMed ID: 9166518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
    Li C; Hall WA; Jin N; Todhunter DA; Panoskaltsis-Mortari A; Vallera DA
    Protein Eng; 2002 May; 15(5):419-27. PubMed ID: 12034862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.
    Yang X; Kessler E; Su LJ; Thorburn A; Frankel AE; Li Y; La Rosa FG; Shen J; Li CY; Varella-Garcia M; Glodé LM; Flaig TW
    Clin Cancer Res; 2013 Jan; 19(1):148-57. PubMed ID: 23172881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins.
    Shaw JP; Akiyoshi DE; Arrigo DA; Rhoad AE; Sullivan B; Thomas J; Genbauffe FS; Bacha P; Nichols JC
    J Biol Chem; 1991 Nov; 266(31):21118-24. PubMed ID: 1939154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
    Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
    Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells.
    Liu TF; Cohen KA; Ramage JG; Willingham MC; Thorburn AM; Frankel AE
    Cancer Res; 2003 Apr; 63(8):1834-7. PubMed ID: 12702570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor-targeted cytotoxin inhibits neointimal hyperplasia in vivo. Results of local versus systemic administration.
    Pastore CJ; Isner JM; Bacha PA; Kearney M; Pickering JG
    Circ Res; 1995 Sep; 77(3):519-29. PubMed ID: 7641322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
    Hall WA; Vallera DA
    Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.
    Qi Z; Qiu Y; Wang Z; Zhang H; Lu L; Liu Y; Mathes D; Pomfret EA; Gao D; Lu SL; Wang Z
    Mol Oncol; 2021 Apr; 15(4):1054-1068. PubMed ID: 33540470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
    Rustamzadeh E; Li C; Doumbia S; Hall WA; Vallera DA
    J Neurooncol; 2003 Oct; 65(1):63-75. PubMed ID: 14649886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
    Vallera DA; Li C; Jin N; Panoskaltsis-Mortari A; Hall WA
    J Natl Cancer Inst; 2002 Apr; 94(8):597-606. PubMed ID: 11959893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
    Huang J; Li YM; Massague J; Sicheneder A; Vallera DA; Hall WA
    J Neurooncol; 2012 Sep; 109(2):229-38. PubMed ID: 22696210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting diphtheria toxin to growth factor receptors.
    Murphy JR; vanderSpek JC
    Semin Cancer Biol; 1995 Oct; 6(5):259-67. PubMed ID: 8562903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the EGF receptor in breast cancer treatment.
    LeMaistre CF; Meneghetti C; Howes L; Osborne CK
    Breast Cancer Res Treat; 1994; 32(1):97-103. PubMed ID: 7819590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.
    Wood DP
    J Urol; 2014 Feb; 191(2):556. PubMed ID: 24411908
    [No Abstract]   [Full Text] [Related]  

  • 20. Diphtheria fusion protein therapy of chemoresistant malignancies.
    Frankel AE; Rossi P; Kuzel TM; Foss F
    Curr Cancer Drug Targets; 2002 Mar; 2(1):19-36. PubMed ID: 12188918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.